Contrasting Omeros (NASDAQ:OMER) and Green Thumb Industries (OTCMKTS:GTBIF)

Green Thumb Industries (OTCMKTS:GTBIF) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Green Thumb Industries and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Green Thumb Industries	3.77%	1.66%	1.17%
Omeros	N/A	N/A	-52.38%

Valuation and Earnings

This table compares Green Thumb Industries and Omeros”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Green Thumb Industries	$1.14 billion	1.16	$73.08 million	$0.17	37.51
Omeros	N/A	N/A	-$156.82 million	($2.02)	-5.51

Green Thumb Industries has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Green Thumb Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Green Thumb Industries and Omeros, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Green Thumb Industries	0	1	1	1	3.00
Omeros	1	1	2	1	2.60

Omeros has a consensus target price of $40.33, suggesting a potential upside of 262.06%. Given Omeros’ higher probable upside, analysts clearly believe Omeros is more favorable than Green Thumb Industries.

Volatility and Risk

Green Thumb Industries has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Omeros has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Green Thumb Industries shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 9.4% of Green Thumb Industries shares are owned by insiders. Comparatively, 12.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Green Thumb Industries beats Omeros on 8 of the 13 factors compared between the two stocks.

About Green Thumb Industries

Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.